Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Early research (Phase 1)Ended earlyNCT02608125
What this trial is testing

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Who this might be right for
Solid TumorsMetastatic Urothelial Carcinoma & Renal Pelvis & Ureter
Principia Biopharma, a Sanofi Company 45
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714
What this trial is testing

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more
National Cancer Institute (NCI) 20